http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006524203-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 |
| filingDate | 2004-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006524203-A |
| titleOfInvention | Use of dipyridamole or mopidamol for the treatment and prevention of thromboembolic diseases and disorders caused by thrombin over-formation and / or increased expression of thrombin receptor |
| abstract | A method of treating the body of a human or non-human animal for the treatment or prevention of diseases caused by increased thrombin or thrombin receptor expression, such as thromboembolic disease vascular syndrome or proliferative disease, said method comprising Administering an effective amount of a pharmaceutical composition comprising dipyridamole, mopidamol or a pharmaceutically acceptable salt thereof to a human or non-human animal body in need of such treatment, and corresponding pharmaceutical compositions, and Disclosed is the use of dipyridamole or mopidamol for the manufacture of a pharmaceutical composition. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012500244-A |
| priorityDate | 2003-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 311.